Although the combination of HAIC, lenvatinib and PD-1 inhibitors has been extensively evaluated in the treatment of advanced hepatocellular carcinoma, their roles in advanced CCA remain poorly understood. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.